Soligenix Inc. (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology
February 10, 2026
From lab research to clinical application, photodynamic therapy (“PDT”) is emerging as a powerful treatment approach that uses light and chemistry to selectively target diseased tissue. As this modality gains attention for its precision and safety profile, Soligenix (NASDAQ: SNGX) is developing light-activated therapies designed to treat cutaneous T-cell lymphoma (“CTCL”) and other inflammatory skin […]
InvestorNewsBreaks – Soligenix Inc.’s (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach
February 6, 2026
Soligenix (NASDAQ: SNGX) was featured in a recent article that discussed the company’s release of positive top-line results from its phase 2 clinical trial evaluating SGX945 for the treatment of aphthous ulcers associated with Behçet’s. “Behçet’s disease is a rare, chronic inflammatory condition that can cause recurrent, painful ulcers, eye inflammation and systemic complications that […]
Soligenix Inc. (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer
February 2, 2026
Cutaneous T-cell lymphoma (“CTCL”) remains a cancer with limited treatment options, persistent symptoms and long-term quality-of-life challenges for patients, even decades after its classification as a distinct disease. Despite medical advances in oncology, many people living with CTCL continue to cycle through therapies that offer only partial relief or introduce new burdens. Soligenix (NASDAQ: SNGX) […]
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
January 30, 2026
As the global burden of rare diseases continues to rise, there is increasing urgency for innovative therapies that address unmet medical needs. More than 300 million people worldwide live with one or more rare diseases, many of which have limited or no approved treatment options, and diagnostic delays can persist for years, prolonging suffering and […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM)
January 29, 2026
Cutaneous T-cell lymphoma, or CTCL, is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early stages. A recent article discussed Soligenix’s (NASDAQ: SNGX) efforts to develop therapies aimed at addressing critical gaps in rare disease treatment, including CTCL. The publication reads, “Within a challenging diagnostic and treatment landscape, Soligenix is advancing a novel therapeutic […]
InvestorNewsBreaks – RiVax(R) Positions Soligenix Inc. (NASDAQ: SNGX) in Growing Biodefense Preparedness Efforts
January 23, 2026
Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, was featured in a recent article discussing its development of a vaccine candidate known as RiVax(R) to protect against ricin exposure. These efforts position the company at the center of biodefense preparedness as public awareness of ricin’s lethality grows. “In a counter-terrorism operation in India, […]
Soligenix Inc. (NASDAQ: SNGX) Announces Positive Phase 2 Data for Rare Inflammatory Disease
January 16, 2026
Behçet’s disease is a rare, chronic inflammatory condition that can cause recurrent, painful ulcers, eye inflammation and systemic complications that significantly affect quality of life. Because available treatments are limited and often inconsistent, clinical trial updates in this disease area carry particular importance. Soligenix (NASDAQ: SNGX) is reporting results from a phase 2a proof of […]
Soligenix Inc. (NASDAQ: SNGX) Advances Solutions for Hard-to-Diagnose CTCL
January 14, 2026
Cutaneous T-cell lymphoma, or CTCL, is a rare form of non-Hodgkin lymphoma that primarily affects the skin, often presenting with symptoms that closely resemble common dermatologic conditions such as eczema or psoriasis, leading to frequent misdiagnosis and delayed treatment. These diagnostic delays can allow the disease to progress silently for years, increasing patient suffering and […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reaches Enrollment Milestone in Phase 3 FLASH2 Trial for HyBryte(TM)
January 9, 2026
Soligenix (NASDAQ: SNGX) is a New Jersey-based biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need. The company recently received updated analysis from Zacks Small-Cap Research following its announcement that milestone enrollment had been reached in the ongoing confirmatory Phase 3 FLASH2 trial of HyBryte(TM). The study […]
Soligenix Inc. (NASDAQ: SNGX) Extends SGX302 Clinical Success in Phase 2A Psoriasis Study
December 22, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases where unmet medical need exists, announced extended top line results from its Phase 2a clinical trial of SGX302 (synthetic hypericin) in patients with mild-to-moderate psoriasis. The updated findings highlight clinical improvements with an optimized gel formulation of the investigational […]
Soligenix Inc. (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat
December 19, 2025
A recent “Times of India” report spotlighted the danger posed by ricin, a highly toxic plant-derived compound with no known antidote and a history of attempted misuse by extremist actors. Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, is developing a vaccine candidate known as RiVax(R) to protect against ricin exposure, positioning the company’s work at the […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease
December 18, 2025
Soligenix (NASDAQ: SNGX) announced that results from its Phase 2a proof-of-concept study evaluating SGX945 (dusquetide) for the treatment of aphthous ulcers associated with Behçet’s Disease have been published in Rheumatology (Oxford), reporting beneficial effects in seven of eight patients with sustained improvement through a four-week follow-up period after treatment ended. The company said outcomes for SGX945, including reductions in […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis
December 17, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases with unmet medical need, reported extended results from its ongoing Phase 2a trial evaluating SGX302 (synthetic hypericin) for mild-to-moderate psoriasis, including outcomes from an additional cohort treated with an optimized topical gel formulation. The gel was well tolerated with no drug-related adverse […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in NetworkNewsAudio APR on Urgent Need for Rare Disease Therapies
December 10, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, is highlighted in a new NetworkNewsAudio APR titled “Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now.” The feature underscores the growing impact of chronic and rare conditions on older adults, with more than 30 million Americans affected […]
Soligenix Inc. (NASDAQ: SNGX) Receives Strong Vote of Confidence from Zacks Report Despite Muted Market Response to Clinical Milestone
December 8, 2025
When a late-stage clinical trial reports response rates nearly double what researchers expected, yet the stock market barely reacts, seasoned analysts take notice and wonder if investors are missing something significant. Soligenix (NASDAQ: SNGX), a New Jersey-based biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need, recently […]
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
December 5, 2025
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) — via BioMedWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (“BMW”), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies
December 5, 2025
Soligenix (NASDAQ: SNGX), announces its inclusion in a BioMedWire editorial examining the urgent rise of chronic and rare diseases in aging populations. With more than 30 million Americans living with rare disorders that often lack FDA-approved treatments, demand for novel therapies continues to grow. Soligenix is advancing late-stage programs including HyBryte(TM) for cutaneous T-cell lymphoma, […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial Highlighting HyBryte(TM) and Rare Disease Policy
December 3, 2025
Soligenix (NASDAQ: SNGX) was featured in a BioMedWire editorial titled “Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,” which examines the growing burden of rare diseases affecting more than 30 million Americans and the urgent need for new therapies. The article spotlights Soligenix’s late-stage development of HyBryte(TM) (synthetic hypericin) […]
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
December 3, 2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) — via BioMedWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (“BMW”), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the […]
Soligenix Inc. (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate
December 1, 2025
In a pivotal advancement for patients suffering from a rare form of skin cancer, Soligenix (NASDAQ: SNGX) has achieved a critical clinical trial milestone that brings its investigational treatment significantly closer to potential FDA approval. The company announced that is has completed the planned enrollment of 50 patients necessary for the interim analysis in its […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data
November 28, 2025
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines. The company recently published a peer-reviewed summary of new scientific data demonstrating long-term high-temperature stability of its protein subunit vaccine platform designed for Ebola and Marburg-related viruses. An article discussing this reads, “Soligenix has been developing formulations intended to remain […]
Soligenix Inc. (NASDAQ: SNGX) Elevates Advisory Network as Rare Disease Strategy Advances
November 25, 2025
Soligenix (NASDAQ: SNGX) is entering a new phase of strategic breadth and influence with the appointment of a seasoned, high-level scientific and policy adviser who brings rarefied experience at the intersection of economics, government and healthcare innovation. The company, a late-stage biopharmaceutical firm developing treatments for rare diseases, has announced the appointment of Tomas J. […]
Soligenix Inc. (NASDAQ: SNGX) Strengthens CTCL Program as DMC Flags No Safety Issues
November 24, 2025
In a key development that underscores the advancing clinical trajectory of its lead therapy, Soligenix (NASDAQ: SNGX) announced that the Data Monitoring Committee (“DMC”) overseeing its confirmatory Phase 3 FLASH2 trial of HyBryte(TM) has reported no safety concerns to date, affirming the therapy’s safety profile. Soligenix, a biopharmaceutical company focused on rare diseases and treatments […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte
November 19, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases with unmet medical need, completed enrollment of the 50 patients required for the interim analysis in its 80-patient confirmatory Phase 3 FLASH2 study evaluating HyBryte (TM) in cutaneous T-cell lymphoma. The interim analysis is slated for the second quarter of 2026, with topline […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Key Clinical Progress and Reports Q3 2025 Financial Results
November 7, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company advancing treatments for rare diseases with unmet medical need, reported third quarter 2025 results and outlined upcoming milestones, including top-line Phase 2a results for SGX302 in psoriasis and an enrollment update for its confirmatory Phase 3 HyBryte(TM) study in cutaneous T-cell lymphoma (CTCL). CEO Christopher J. Schaber, PhD, […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Eyes Dermatology Market with SGX302’s Encouraging Early Results
November 6, 2025
Soligenix (NASDAQ: SNGX) is advancing its phase 2a clinical trial of SGX302, a synthetic hypericin therapy for mild-to-moderate psoriasis, building on promising phase 1/2 data. Early results from the trial show encouraging signs of safety and biological activity, highlighting SGX302’s potential as a novel, well-tolerated treatment for a chronic autoimmune skin condition affecting millions globally. […]
Soligenix Inc. (NASDAQ: SNGX) Strengthens Financial Foundation to Advance Multiple Value Drivers
November 4, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and biodefense programs, continues to fortify its financial position as it advances toward a series of pivotal and potentially transformational milestones. Following a series of strategic capital initiatives, including a $7.5 million public offering (https://ibn.fm/QKXcv), the company now reports a cash runway extending through […]
Soligenix Inc. (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma
November 3, 2025
Soligenix (NASDAQ: SNGX), a clinical-stage biotechnology company focused on rare diseases and public health solutions, has rejuvenated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (“CTCL”), placing fresh expertise and leadership at the center of its HyBryte(TM) development program (https://ibn.fm/ueKOC). This strategic move signals the company’s deepening commitment to advancing its pipeline agents in […]
Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability
October 28, 2025
Current vaccines for Ebola and similar filoviruses face a major deployment barrier: Most require storage between 2°C and 8°C throughout transport, making them vulnerable to spoilage when exposed to the high ambient heat common in many outbreak regions (https://ibn.fm/MZWfk). Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines, has published […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances HyBryte(TM) as Potential First-Line CTCL Treatment with Promising FLASH Results
October 22, 2025
Soligenix (NASDAQ: SNGX) is continuing to build momentum in the treatment of early-stage cutaneous T-cell lymphoma (“CTCL”) through promising results from its pivotal FLASH trial and ongoing FLASH 2 confirmatory study. HyBryte(TM)—a novel, non-UV light-activated therapy using synthetic hypericin—has demonstrated statistically significant efficacy and safety, offering hope in a field where therapeutic innovation has lagged. […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Updates U.S. Medical Advisory Board to Advance Phase 3 Development of HyBryte for CTCL
October 14, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced updates to its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (CTCL) to support the ongoing Phase 3 development of HyBryte(TM) (synthetic hypericin). The board, comprised of leading dermatologic and oncologic experts, will provide strategic guidance as Soligenix advances regulatory and […]
Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026
October 13, 2025
Soligenix (NASDAQ: SNGX) recently announced the closing of a $7.5 million public offering, providing the company with additional capital to advance its pipeline (https://ibn.fm/tCsub). This funding extends Soligenix’s cash runway through the end of 2026, ensuring that the company has the financial resources to reach key inflection points across its portfolio, including late-stage clinical trials […]
Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL
October 9, 2025
Cutaneous T-cell lymphoma (“CTCL”) is a rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. Globally, millions suffer from CTCL, and in Europe, the annual incidence is estimated at 2.9 to 3.9 cases per million people (https://ibn.fm/ANk8X). Despite its rarity, CTCL presents a substantial unmet medical need, particularly in early-stage patients who […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reports Positive Safety Review from DMC in Ongoing Phase 3 FLASH2 Study of HyBryte for CTCL
October 7, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, announced that its Data Monitoring Committee has completed its first review of the confirmatory Phase 3 FLASH2 study of HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma, concluding there are no safety concerns and that the therapy maintains an acceptable safety profile consistent with […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Closes $7.5 Million Public Offering to Extend Cash Runway Through 2026
October 1, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the closing of its $7.5 million public offering of 5,555,560 shares of common stock and accompanying warrants at $1.35 per share, with proceeds intended to fund R&D, commercialization, working capital, and general corporate purposes; the financing, which included participation from existing […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board to Advance HyBryte Phase 3 Study
September 30, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the expansion of its European Medical Advisory Board to guide its confirmatory Phase 3 trial of HyBryte(TM) in early-stage cutaneous T-cell lymphoma, an 18-week study enrolling about 80 patients with top-line results expected in the second half of 2026, as the […]
Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential
September 29, 2025
Psoriasis remains a persistent challenge for millions of patients worldwide, and promising new treatments are being closely watched by the medical and investor communities alike. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and inflammatory conditions, is advancing its treatment candidate, SGX302, in a phase 2a clinical trial for mild-to-moderate psoriasis. The […]
Soligenix Inc. (NASDAQ: SNGX) Strengthens Position in CTCL Treatment with HyBryte(TM) FLASH Results
September 24, 2025
Soligenix (NASDAQ: SNGX) is continuing to build momentum in its mission to advance HyBryte(TM), a first-in-class treatment for early-stage cutaneous T-cell lymphoma (“CTCL”). That progress is supported by results from its pivotal FLASH trial and its ongoing FLASH 2 confirmatory study. Together, the studies highlight not only the efficacy of synthetic hypericin activated by safe […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Appoints Tomas J. Philipson, PhD as Strategic Advisor
September 23, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson, an expert in U.S. economic and healthcare policy with extensive academic, business, and government experience, previously served as acting chairman of the White House […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Leveraging Positive Clinical Data to Shape Pivotal SGX942 Trial
September 19, 2025
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical need. The company’s SGX942 is a novel therapeutic aimed at alleviating oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment. “Severe oral mucositis (‘SOM’) often necessitates hospitalization, opioid pain management […]